1. Home
  2. VSTS vs RAPP Comparison

VSTS vs RAPP Comparison

Compare VSTS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$14.56

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$41.40

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
RAPP
Founded
1936
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2023
2024

Fundamental Metrics

Financial Performance
Metric
VSTS
RAPP
Price
$14.56
$41.40
Analyst Decision
Sell
Strong Buy
Analyst Count
4
6
Target Price
$5.88
$48.50
AVG Volume (30 Days)
1.2M
354.0K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
$2,734,839,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$13.64
52 Week High
$16.90
$44.28

Technical Indicators

Market Signals
Indicator
VSTS
RAPP
Relative Strength Index (RSI) 48.20 51.35
Support Level $13.40 $38.55
Resistance Level $15.06 $43.89
Average True Range (ATR) 0.61 2.43
MACD -0.22 -0.10
Stochastic Oscillator 11.72 42.93

Price Performance

Historical Comparison
VSTS
RAPP

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: